Bright Peak Therapeutics Inc. and Ajinomoto Co., Inc. Enter into a Research Collaboration and License Agreement to Create Novel Immunocytokines

SAN DIEGO and TOKYO, March 25, 2021 (GLOBE NEWSWIRE) — Brilliant Peak Therapeutics Inc., a biotechnology firm creating subsequent technology immunotherapies for most cancers and autoimmune illness, and Ajinomoto Co., Inc. (“Ajinomoto Co.”), a number one know-how supplier for biopharmaceuticals and the proprietor of Ajinomoto Bio-Pharma Companies providing pharmaceutical contract growth and manufacturing providers, at present introduced a analysis collaboration and unique license settlement to include AJICAP®,  Ajinomoto Co.’s proprietary site-specific bioconjugation know-how, for the event of Brilliant Peak Immunocytokines.Brilliant Peak makes use of a novel ligation know-how to chemically synthesize therapeutic cytokines by ligating collectively personalized peptide segments. This proprietary platform supplies distinctive flexibility to each tune and improve cytokine biology by means of affinity modification and orthogonal, site-specific conjugation, respectively. AJICAP® is a proprietary site-specific bioconjugation know-how suitable with generally used antibody isotypes. One of many many benefits of AJICAP® know-how is its “off-the-shelf” characteristic, permitting any therapeutic antibody at any stage of growth to be conjugated to drug-payloads of selection with out the necessity for antibody engineering or cell line growth.As a part of the collaboration and license settlement with Ajinomoto Co., the AJICAP® know-how shall be used to conjugate Brilliant Peak’s enhanced cytokines as payloads to sure antibodies, creating novel and proprietary Brilliant Peak Immunocytokines. These Immunocytokines will enable tissue- and cell-specific concentrating on of the cytokine payload with the added potential for synergistic efficacy by means of potency-enhancing avidity results. As a part of the settlement, Brilliant Peak will obtain unique worldwide rights to make use of the AJICAP® know-how for the conjugation of sure cytokine payloads, together with however not restricted to interleukin-2 (IL-2). The settlement is for the event of multi Immunocytokine molecules. Underneath the phrases of the settlement, Brilliant Peak will make an exclusivity cost and Ajinomoto Co. is eligible to obtain growth, regulatory and business milestone funds in addition to royalties on business gross sales.“We’re delighted to announce the collaboration with Ajinomoto develop our proprietary Immunocytokines utilizing AJICAP® know-how. It’s a pure extension of Brilliant Peak’s chemical synthesis know-how platform. The AJICAP® conjugation know-how is ideally suited to conjugate our enhanced cytokines as payloads to antibodies within the most cancers and autoimmune subject” stated Dr. Sef Kurstjens President and CEO of Brilliant Peak Therapeutics, Inc.Dr. Tatsuya Okuzumi, Affiliate Normal Supervisor, Analysis and Enterprise Planning Division, Ajinomoto Co., Inc., added, “Ajinomoto Co. and Ajinomoto Bio-Pharma Companies are very excited to collaborate with Brilliant Peak within the growth of focused Immunocytokines. The flexibility to direct potent, homogeneous immune-signaling molecules to tumors and the tumor microenvironment could present enhanced antitumor scientific profit by means of immune cell cytotoxic exercise. The mix of Brilliant Peak’s cytokine payloads with Ajinomoto Co.’s AJICAP® opens up a variety of oncology purposes and could also be harnessed to offer a scientific profit to sufferers.”About Brilliant Peak Therapeutics – Brilliant Peak is a privately held biotechnology firm based mostly in San Diego, CA and Basel, Switzerland creating progressive cytokine therapeutics which are uniquely engineered to exactly tune and management desired organic properties. Utilizing its proprietary Enhanced Design and Mix (EDC) chemistry platform, Brilliant Peak is creating an rising portfolio of novel designer immunotherapies for the therapy of most cancers and autoimmune illnesses. Brilliant Peak can also be pioneering a brand new class of “Brilliant Peak Immunocytokines” that concurrently leverages the precision of antibody concentrating on with cytokine-mediated selective immune modulation within the desired microenvironment.Contact:

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *